5 news items
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
LXRX
2 May 24
, chronic kidney disease, and other cardiovascular risk factors IMPORTANT SAFETY INFORMATION
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
LXRX
25 Mar 24
kidney disease, and other cardiovascular risk factors IMPORTANT SAFETY INFORMATION
Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis Of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment In Patients With Type 1 Diabetes And Chronic Kidney Disease
LXRX
12 Mar 24
with sotagliflozin successfully lowered A1C, body weight, and systolic blood pressure with safety similar to the total study cohort
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
ATXI
BALY
BIAF
11 Mar 24
% to $3.43. Rail Vision received an order from a Class 1 US railroad company for its AI-based safety system.
Marpai, Inc
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
LXRX
11 Mar 24
kidney disease, and other cardiovascular risk factors IMPORTANT SAFETY INFORMATION
- Prev
- 1
- Next